CR7442A - Derivados de benzimidazol 1-fenil-2- heteroaril- sustituidos, su uso para preparar medicamentos para el tratamiento de enfermedades inmunologicas - Google Patents

Derivados de benzimidazol 1-fenil-2- heteroaril- sustituidos, su uso para preparar medicamentos para el tratamiento de enfermedades inmunologicas

Info

Publication number
CR7442A
CR7442A CR7442A CR7442A CR7442A CR 7442 A CR7442 A CR 7442A CR 7442 A CR7442 A CR 7442A CR 7442 A CR7442 A CR 7442A CR 7442 A CR7442 A CR 7442A
Authority
CR
Costa Rica
Prior art keywords
treatment
derivatives
heteroaril
fenil
benzimidazol
Prior art date
Application number
CR7442A
Other languages
English (en)
Inventor
Thorsten Blume
Wolfang Halfbrodt
Joachim Kuhnke
Ursula Monning
Bernd Elger
Herbert Schneider
Original Assignee
Shering Aktiengellsschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shering Aktiengellsschaft filed Critical Shering Aktiengellsschaft
Publication of CR7442A publication Critical patent/CR7442A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen derivados de benzimidazol , su preparacion y su uso para preparar medicamente para el tratamiento y la profilaxis de enfermedades que estan asociadas con la activacion de la microglia, y enfermedades inmunologicas mediadas por celulas T asi como preparados farmaceuticos que contienen los nuevos derivados de benzimidazol.
CR7442A 2002-02-15 2004-09-01 Derivados de benzimidazol 1-fenil-2- heteroaril- sustituidos, su uso para preparar medicamentos para el tratamiento de enfermedades inmunologicas CR7442A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10207844A DE10207844A1 (de) 2002-02-15 2002-02-15 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
CR7442A true CR7442A (es) 2006-02-06

Family

ID=27674913

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7442A CR7442A (es) 2002-02-15 2004-09-01 Derivados de benzimidazol 1-fenil-2- heteroaril- sustituidos, su uso para preparar medicamentos para el tratamiento de enfermedades inmunologicas

Country Status (30)

Country Link
EP (1) EP1474415B1 (es)
JP (1) JP4739675B2 (es)
KR (1) KR101027556B1 (es)
CN (1) CN1317274C (es)
AR (1) AR038492A1 (es)
AT (1) ATE517881T1 (es)
AU (1) AU2003205624B2 (es)
BR (1) BR0307723A (es)
CA (1) CA2475780C (es)
CR (1) CR7442A (es)
CY (1) CY1113230T1 (es)
DE (1) DE10207844A1 (es)
DK (1) DK1474415T3 (es)
EC (1) ECSP045296A (es)
ES (1) ES2369662T3 (es)
IL (1) IL163431A (es)
MX (1) MXPA04007949A (es)
NO (1) NO329667B1 (es)
NZ (1) NZ534660A (es)
PE (1) PE20030941A1 (es)
PL (1) PL216233B1 (es)
PT (1) PT1474415E (es)
RS (1) RS51831B (es)
RU (1) RU2325384C2 (es)
SI (1) SI1474415T1 (es)
TW (1) TWI328583B (es)
UA (1) UA81243C2 (es)
UY (1) UY27661A1 (es)
WO (1) WO2003068766A1 (es)
ZA (1) ZA200407381B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1497266T3 (da) 2002-03-27 2008-10-06 Glaxo Group Ltd Quinolinderivater og deres anvendelse som 5HT6-ligander
CN1787817B (zh) * 2003-05-19 2011-09-07 Irm责任有限公司 免疫抑制剂化合物及组合物
WO2014044611A1 (en) 2012-09-20 2014-03-27 Bayer Pharma Aktiengesellschaft 1-aryl-2-heteroaryl benzimidazoles for the induction of neuronal regeneration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4330959A1 (de) * 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
MXPA02005742A (es) 2000-01-14 2002-09-18 Schering Ag 1,2-diaril bencimidazoles para el tratamiento de enfermedades asociadas con la activacion de la micrologia.
US7115645B2 (en) * 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen

Also Published As

Publication number Publication date
TW200303307A (en) 2003-09-01
SI1474415T1 (sl) 2011-12-30
RU2004127678A (ru) 2005-07-10
CY1113230T1 (el) 2016-04-13
WO2003068766A1 (de) 2003-08-21
BR0307723A (pt) 2005-01-25
KR101027556B1 (ko) 2011-04-06
IL163431A (en) 2010-11-30
UA81243C2 (en) 2007-12-25
RS51831B (en) 2012-02-29
JP4739675B2 (ja) 2011-08-03
RS71404A (en) 2006-10-27
CN1633429A (zh) 2005-06-29
ZA200407381B (en) 2005-11-30
KR20040081795A (ko) 2004-09-22
TWI328583B (en) 2010-08-11
AU2003205624B2 (en) 2009-08-27
JP2005521686A (ja) 2005-07-21
CA2475780C (en) 2011-08-02
ATE517881T1 (de) 2011-08-15
AR038492A1 (es) 2005-01-19
PL216233B1 (pl) 2014-03-31
ECSP045296A (es) 2004-10-26
CA2475780A1 (en) 2003-08-21
EP1474415B1 (de) 2011-07-27
DE10207844A1 (de) 2003-09-04
DK1474415T3 (da) 2011-11-21
RU2325384C2 (ru) 2008-05-27
CN1317274C (zh) 2007-05-23
UY27661A1 (es) 2003-09-30
PL371269A1 (en) 2005-06-13
PT1474415E (pt) 2011-10-13
NO329667B1 (no) 2010-11-29
NZ534660A (en) 2006-02-24
EP1474415A1 (de) 2004-11-10
PE20030941A1 (es) 2004-01-17
ES2369662T3 (es) 2011-12-02
NO20043841L (no) 2004-11-12
MXPA04007949A (es) 2004-11-26
AU2003205624A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
AR039985A1 (es) Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima
UY30321A1 (es) Procedimiento para preparar medicamentos caracterizado por el uso de derivados sustituidos de la 3-metil-7-(2-butin-1-il) xantina y aplicaciones
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
CL2008002852A1 (es) Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
HN2003000196A (es) Derivados de indolinfenilsulfonamida
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
ECSP077349A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
ECSP10010197A (es) Derivados de piridina y pirazina útiles en el tratamiento de trastornos de proliferación celular
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
CO2021000043A2 (es) Degradadores selectivos del receptor de estrógeno
UY27760A1 (es) Nuevos derivados de pirrolidinio.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
CR10900A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
ECSP12011716A (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
SV2003001148A (es) Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv
ECSP077259A (es) Derivados de pirimidina
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
BRPI0517792A (pt) macrolonas - quinolonas amino-substituìdas
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
CL2008002747A1 (es) Compuestos derivados de furo y tienopirimidina; composicion farmaceutica; metodo para modular la actividad del receptor de histamina h4; y uso en el tratamiento de trastornos tales como inflamacion, trastornos alergicos, dermatologicos, entre otros.

Legal Events

Date Code Title Description
FC90 Application suspended